Centene (NYSE:CNC)‘s stock had its “buy” rating reaffirmed by investment analysts at Oppenheimer in a note issued to investors on Friday. They currently have a $111.00 price target on the stock. Oppenheimer’s price objective points to a potential upside of 12.10% from the stock’s previous close.

Other research analysts have also recently issued research reports about the stock. Leerink Swann reaffirmed a “market perform” rating and issued a $90.00 price target (up previously from $78.00) on shares of Centene in a report on Wednesday, September 13th. Cowen reaffirmed an “outperform” rating and issued a $105.00 price target (up previously from $77.00) on shares of Centene in a report on Wednesday, September 13th. BidaskClub raised shares of Centene from a “hold” rating to a “buy” rating in a report on Thursday, August 24th. Piper Jaffray Companies reaffirmed a “buy” rating and issued a $105.00 price target on shares of Centene in a report on Friday, September 1st. Finally, Morgan Stanley raised their price target on shares of Centene from $94.00 to $103.00 and gave the stock an “overweight” rating in a report on Thursday, September 21st. One investment analyst has rated the stock with a sell rating, three have given a hold rating and seventeen have issued a buy rating to the stock. Centene presently has a consensus rating of “Buy” and an average price target of $99.11.

Centene (CNC) traded down $2.17 during trading hours on Friday, reaching $99.02. 1,326,500 shares of the company were exchanged, compared to its average volume of 1,674,925. Centene has a 12 month low of $54.40 and a 12 month high of $103.15. The company has a debt-to-equity ratio of 0.71, a current ratio of 0.99 and a quick ratio of 0.99. The stock has a market capitalization of $17,462.00, a PE ratio of 19.27, a price-to-earnings-growth ratio of 1.54 and a beta of 0.71.

Centene (NYSE:CNC) last posted its earnings results on Tuesday, October 24th. The company reported $1.35 EPS for the quarter, beating the Zacks’ consensus estimate of $1.24 by $0.11. Centene had a net margin of 1.81% and a return on equity of 14.79%. The company had revenue of $11.90 billion during the quarter, compared to analysts’ expectations of $11.75 billion. During the same quarter in the prior year, the company posted $1.12 earnings per share. Centene’s revenue for the quarter was up 9.7% compared to the same quarter last year. equities analysts anticipate that Centene will post 4.98 earnings per share for the current fiscal year.

In related news, Director Robert K. Ditmore sold 4,167 shares of the firm’s stock in a transaction on Thursday, October 26th. The shares were sold at an average price of $90.42, for a total transaction of $376,780.14. The transaction was disclosed in a document filed with the SEC, which is available at this link. 3.00% of the stock is currently owned by company insiders.

Institutional investors and hedge funds have recently bought and sold shares of the business. Vanguard Group Inc. lifted its stake in shares of Centene by 4.9% in the second quarter. Vanguard Group Inc. now owns 16,726,500 shares of the company’s stock worth $1,336,113,000 after buying an additional 774,474 shares in the last quarter. State Street Corp raised its stake in Centene by 0.5% during the second quarter. State Street Corp now owns 7,154,348 shares of the company’s stock worth $571,504,000 after purchasing an additional 35,040 shares during the period. Ameriprise Financial Inc. raised its stake in Centene by 47.8% during the third quarter. Ameriprise Financial Inc. now owns 5,181,047 shares of the company’s stock worth $502,999,000 after purchasing an additional 1,676,688 shares during the period. Wells Fargo & Company MN raised its stake in Centene by 12.4% during the second quarter. Wells Fargo & Company MN now owns 4,193,466 shares of the company’s stock worth $334,973,000 after purchasing an additional 462,936 shares during the period. Finally, Dimensional Fund Advisors LP raised its stake in Centene by 6.7% during the third quarter. Dimensional Fund Advisors LP now owns 2,398,997 shares of the company’s stock worth $232,137,000 after purchasing an additional 149,743 shares during the period. 92.33% of the stock is currently owned by institutional investors and hedge funds.

TRADEMARK VIOLATION NOTICE: This news story was posted by American Banking News and is the sole property of of American Banking News. If you are viewing this news story on another site, it was copied illegally and reposted in violation of United States & international copyright & trademark legislation. The original version of this news story can be viewed at https://www.americanbankingnews.com/2017/12/15/oppenheimer-reaffirms-buy-rating-for-centene-cnc.html.

Centene Company Profile

Centene Corporation is a healthcare company. The Company provides a portfolio of services to government sponsored healthcare programs, focusing on under-insured and uninsured individuals. The Company operates through two segments: Managed Care and Specialty Services. The Company’s Managed Care segment provides health plan coverage to individuals, through government subsidized programs, including Medicaid, the State Children’s Health Insurance Program (CHIP), Long Term Care, Foster Care, dual-eligible individuals (Duals) and the Supplemental Security Income Program, also known as the Aged, Blind or Disabled Program (ABD), Medicare, and Health Insurance Marketplace.

Analyst Recommendations for Centene (NYSE:CNC)

Receive News & Ratings for Centene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Centene and related companies with MarketBeat.com's FREE daily email newsletter.